

Cite this: *Nanoscale*, 2024, **16**, 20147

Effective enrichment of glycosylated proteome using ultrasmall gold nanoclusters functionalized with boronic acid†

Hongmae Heo, ^a Seonghyeon Cho,^{b,c} Yuhyeon Kim,^a Soomin Ahn,^a Jeong-hun Mok, ^d Hookeun Lee ^{*b} and Dongil Lee ^{*a}

Glycosylated proteins play a crucial role in various biological pathways and the pathogenesis of human diseases. A comprehensive analysis of glycosylated proteins is essential for understanding their biological significance. However, their low abundance and heterogeneity in complex biological samples necessitate an enrichment procedure prior to their detection. Current enrichment strategies primarily rely on the boronic acid (BA) affinity method combined with functional nanoparticles; however, the effectiveness of these approaches is often suboptimal. In this study, a novel nanocluster (NC)-based enrichment material was synthesized for the first time, characterized as Au₂₂SG₁₈ functionalized with 24 BA groups, in which SG is glutathione. The functionalized BA established a reversible covalent bond with the *cis*-dihydroxy group through pH adjustment, enabling selective enrichment of glycosylated peptides. After the optimization of the enrichment protocol, we demonstrated highly sensitive and selective enrichment of standard glycopeptides using the NC-based enrichment material, exhibiting excellent reusability. Efficient enrichment was also demonstrated for the glycosylated proteome from human serum. These results highlight the potential of the atomically well-defined ultrasmall Au NCs as a powerful tool for high-throughput analysis of glycosylated peptides.

Received 9th August 2024,
Accepted 6th October 2024

DOI: 10.1039/d4nr03283g

rsc.li/nanoscale

1. Introduction

Glycation, also called non-enzymatic glycosylation, is one of the most common protein post-translational modifications resulting from the spontaneous covalent addition of reducing sugars to proteins through the Maillard reaction.¹ The active aldehyde group of a reducing sugar reacts with the nucleophilic free amino group of a protein to form a reversible Schiff base, which is then rearranged to form stable Amadori compounds, defined as the early-stage glycation products. These compounds further convert to advanced glycation end products through several subsequent reactions.² Indeed, Aberrant glycation is strongly associated with various human diseases, such as diabetes, Alzheimer's disease, cardiovascular disorders, renal disease, and cancer.^{3–7}

An expanding body of research indicated that glycosylated proteins can serve as potential biomarkers for early disease diagnosis and prognosis. Thus, conducting a comprehensive analysis of the glycosylated proteome is crucial to provide a comprehensive understanding of the role of glycation in both normal physiological processes and pathological conditions, thereby discovering valuable new disease biomarkers.

Mass spectrometry (MS)-based strategies and corresponding methods have substantially advanced glycoproteome studies.^{8,9} However, challenges such as low abundance, heterogeneity, broad dynamic range of protein glycation, and signal suppression in the presence of nonglycosylated peptides complicate their analysis.^{10,11} For comprehensive proteome research, the selective enrichment of glycosylated proteins from complex biological samples is an essential prerequisite to mass analysis. Among current glycosylated peptide enrichment techniques, boronic acid (BA) affinity chemistry demonstrated considerable potential in universally enriching glycosylated peptides owing to its selective and reversible covalent interaction with *cis*-diols.^{12–16} Although BA-functionalized materials have been widely applied in glycoproteome enrichment,^{17–19} their weak interactions limit their applications in complex samples. Several studies have focused on developing effective stationary phases with BA functional ligands to improve their enrichment

^aDepartment of Chemistry, Yonsei University, Seoul 03722, Republic of Korea.
E-mail: dongil@yonsei.ac.kr

^bCollege of Pharmacy, Gachon University, Incheon 21936, Republic of Korea.
E-mail: hkleee@gachon.ac.kr

^cBasil Biotech, 157-20 Sinsong-ro, Incheon 22002, Republic of Korea

^dDepartment of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul 06355, Republic of Korea

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4nr03283g>

techniques.^{20–23} Wu *et al.* developed an enrichment method using dendrimer beads conjugated with BA derivatives to enhance the glycopeptide enrichment, enabling large-scale analysis of glycoproteins.²⁰ Cao *et al.* fabricated a BA-functionalized mesoporous graphene–silica composite for the efficient and selective enrichment of intact glycopeptides from complex samples.²¹ Teng *et al.* developed a strategy for preparing hollow magnetic nanospheres with large surface areas, realizing improved enrichment performance.²²

Atomically precise Au nanoclusters (NCs) have emerged as a new class of materials owing to their unique physicochemical properties.^{24–28} The unique optical and electrochemical properties and well-defined atomic structures of ultrasmall Au NCs distinguish them from larger nanoparticle systems.^{29–35} In particular, water-soluble NCs have excellent biocompatibility, thereby attracting considerable research interest for biological applications.^{36–42} For example, water-soluble near-infrared (NIR)-emitting Au NCs that can effectively perform *in vivo* tumor-targeted imaging have been reported.^{36–39} In addition, we demonstrated the effective application of highly luminescent Au₂₂ NCs functionalized with folic acids and a pH-responsive dye for bioimaging⁴¹ and intracellular pH sensing,⁴² respectively.

Inspired by these advantages, in this paper, we report the use of ultrasmall Au₂₂ NCs as the stationary phase in BA-based enrichment technique for the first time. We synthesized densely BA-functionalized Au₂₂ NCs and applied them to glycosylated peptide enrichment. The ultrasmall size of the NCs is expected to endow a significantly larger specific surface area than traditional larger nanoparticles, facilitating more effective interactions with target peptides. In addition, the high luminescent properties of Au₂₂ NCs can visualize the isolation process, demonstrating a more effective enrichment. We developed a novel NC-based enrichment protocol and optimized the working conditions to maximize the interactions while minimizing nonspecific bindings. Finally, we demonstrated the effectiveness of this strategy in analyzing the glycosylated proteome of human serum.

2. Results and discussion

2.1. Synthesis of Au₂₂ NCs functionalized with BA

Fig. 1 shows the synthesis scheme of BA-functionalized Au₂₂ NCs (Au₂₂-BA). The starting Au₂₂SG₁₈ NCs, where SG refers to glutathione, were synthesized following a previously reported




Fig. 1 Schematic of the BA-functionalization process of Au₂₂ NCs.

procedure.⁴³ Sequentially, the primary amine group of glutathione was protected with benzyl chloroformate (CBz-Cl) to prevent potential interparticle coupling.³² BA was then covalently conjugated to CBz-protected Au₂₂SG₁₈ (Au₂₂-CBz) through a dicyclohexyl carbodiimide/*N*-hydroxysuccinimide (DCC/NHS) coupling reaction.⁴⁴ Further details are provided in the Experimental section of ESI.† We synthesized Au₂₂ NCs functionalized with two different BA derivatives, namely phenylboronic acid (PBA) and benzoboroxole (BX), with pK_a values of 8.8 and 6.7, respectively (Fig. S1†). The enrichment performance (*vide infra*) of BX-functionalized Au₂₂ NCs (Au₂₂-BX) is better than that of the PBA-functionalized NCs (Au₂₂-PBA); thus, we focused on Au₂₂-BX NCs.

The chemical composition of the starting Au₂₂SG₁₈ NCs was confirmed by electrospray ionization (ESI) MS. As shown in Fig. 2a, the peaks at *m/z* 2460–2480 represent Au₂₂SG₁₈ ions containing various numbers of Na⁺ and H⁺ ions. The experimental isotope pattern of the most prominent peak at approximately *m/z* 2460 Da was superimposed with the simulated one of [Au₂₂SG₁₈-4H]⁴⁻, as depicted in the inset of Fig. 2a. After the coupling reaction, the purified Au₂₂-BX was characterized by optical absorption spectrometry. As shown in Fig. 2b, Au₂₂-BX exhibits a characteristic BX absorption peak, confirming the successful conjugation of BX to the Au₂₂ NC. Moreover, the spectra of Au₂₂-BX depicted a characteristic absorption of Au₂₂SG₁₈ NCs at 520 nm and its photoluminescent (PL) emission peak at approximately 680 nm (Fig. 2b, c and Fig. S2†), indicating the preserved integrity of Au₂₂SG₁₈ NCs during the coupling reaction. Remarkably, the synthesized Au₂₂-BX exhibited intense NIR emission centered at 680 nm, with a quantum




Fig. 2 Characterization of Au₂₂-BX. (a) Negative-ion mode ESI mass spectrum of synthesized Au₂₂SG₁₈. Inset: comparison between the experimental and calculated isotope pattern (blue bar). (b) Optical absorption spectra of Au₂₂SG₁₈, Au₂₂-CBz, Au₂₂-BX, and BX in water. (c) PL spectra ($\lambda_{\text{EX}} = 520$ nm) of Au₂₂SG₁₈, Au₂₂-CBz, and Au₂₂-BX in water. The QYs of the NCs were calibrated using indocyanine green as the standard. (d) TEM image of Au₂₂-BX. The inset shows histograms of the NC core diameter.

yield (QY) of approximately 38.5%, which is nearly five-fold brighter than the original Au₂₂SG₁₈ NCs (Fig. 2c and Fig. S3†). Such result is attributed to the rigidification effect after a series of surface modification processes.^{32,34,43}


Although determining the chemical composition of as-synthesized Au₂₂-BX using MS was challenging owing to its intricate fragmentation pattern, we quantified the number of BX groups conjugated to Au₂₂SG₁₈ using ¹H nuclear magnetic resonance (NMR) spectroscopy. The quantity of conjugated CBz ligands was first determined by comparing the integration number of the CBz peak with the SG ligand peak. As shown in Fig. S4,† the peak at 7.2 ppm pertains to the conjugated CBz ligands, showing a 1.24-fold larger integration number than that of SG, which is centered at 2.2 ppm, indicating that all 18 primary amine groups are fully protected by CBz. Similarly, an average of 24 BX ligands were conjugated per Au₂₂ NC. The polyacrylamide gel electrophoresis (PAGE) separation results in Fig. S5† confirm effective surface functionalization by demonstrating different mobilities of the synthesized NC products. Finally, the transmission electron microscopy (TEM) image depicted the spherical shape of Au₂₂-BX, which is highly monodispersed with an average core size of 1.1 ± 0.1 nm, similar to that of Au₂₂SG₁₈ (Fig. 2d).⁴⁴ Thus, Au₂₂-BX was successfully synthesized. Furthermore, the synthesized Au₂₂-BX NCs exhibit significantly improved stability compared to the initial Au₂₂ NCs (Fig. S6†), ensuring their high potential for practical applications.

2.2. Development of glycosylated peptide enrichment method

BA and its derivatives can readily form reversible covalent bonds with *cis*-diols of sugars by controlling pH and has been widely employed for sugar detection.^{45–47} The peripheral BA of the as-prepared enrichment materials (Au₂₂-BA) can selectively interact with the sugars of glycosylated peptides in an alkaline system, whereas the resulting covalent bonds can be reversibly broken to release glycosylated peptides under an acidic condition. The enrichment of glycosylated peptides by Au₂₂-BA is illustrated in Scheme 1. The process consists of three essential procedures:

incubation, washing, and elution (Experimental section in ESI† for details). During the elution process the bright PL of Au₂₂-BA was utilized to achieve a more effective separation of peptides and NCs (Fig. S7; Experimental section in ESI†). As a proof of concept for this NC-based enrichment method, the capacity of the method was first investigated by employing teicoplanin, a widely recognized glycopeptide antibiotic with a single *cis*-2,3-diol site, as our standard model peptide (Fig. S8†). After completing the enrichment steps, the eluted sample was analyzed using matrix-assisted laser desorption ionization (MALDI) MS. As shown in Fig. S9,† the target peaks of teicoplanin are clearly visible in the mass spectra, demonstrating the feasibility of this method for enriching intact glycosylated peptides. Additionally, two standard glycopeptides, ramoplanin and bleomycin (Fig. S8†), were tested to further assess the sample applicability of our method. Like teicoplanin, ramoplanin with a *cis*-2,3-diol site was clearly detected in the mass spectra after enrichment (Fig. S10a†). The quantity of captured glycopeptides was also measured *via* optical absorption spectrometry (Fig. S11a†), and the effectiveness was determined by calculating the ratio of captured glycopeptides to its initial amount. As shown in Fig. S11b,† Ramoplanin displayed results comparable to teicoplanin, emphasizing the broad sample applicability of this enrichment method. In the case of bleomycin, which lacks a *cis*-diol site and is more challenging to capture, the results demonstrate that while the method remained effective (Fig. S10b†), the capture efficiency was significantly lower compared to the other two glycopeptides (Fig. S11b†), also reflecting sample specificity.

We further refined several crucial parameters in our glycosylated peptide enrichment protocols to achieve optimal enrichment. We implemented control experiments under various conditions using teicoplanin and evaluated the method's effectiveness using optical absorption spectrometry. As the affinity interaction of boronate is highly pH-sensitive, the pH value during incubation should be carefully considered. As such, we performed the incubation procedure under different pH values (7.4, 8.0, 9.0, and 10.0) to analyze the effect of pH. As shown in



Scheme 1 Schematic of the enrichment of glycosylated peptides based on Au₂₂-BA.




Fig. 3 Optimization of enrichment method using standard peptides. (a) Effect of pH on the incubation process. (b) Structures of BA derivatives and their enrichment performance. (c) Effect of NaCl concentration on washing buffer. The results are monitored by the flow-through of vancomycin. The error bar represents the mean standard error, as calculated in triplicate experiments.

Fig. 3a, pH 9.0 yielded the most favorable result, aligning with the commonly accepted concept of more favorable covalent formation of boronate esters under high pH values.^{19,48} At pH 10.0, the performance notably dropped, which can be explained by the poor stability of the peptide samples under high pH conditions.⁴⁹

With the pH condition fixed at 9.0, we optimized the functional ligands. As mentioned earlier, the effective interaction between the peripheral functional ligand and *cis*-diol of glycosylated peptide is vital for the overall effectiveness of the enrichment method. Although PBA has been previously used as a functional ligand, PBA-based methods often suffer from weak interactions.⁵⁰ As such, we investigated BX, a potential BA derivative, as the functional ligand for the newly synthesized NCs. Both PBA- and BX-conjugated NCs were successfully prepared using similar methods (Fig. 1, 2 and Fig. S4, S12†). After conducting parallel experiments to assess the enrichment with standard peptides, Au₂₂ NCs functionalized by BX achieved better enrichment performance compared to those functionalized by PBA (Fig. 3b). The general principle of boronate affinity involves the covalent formation of cyclic esters between a BA ligand and *cis*-diol containing species at pH conditions that are higher than the pK_a of the BA ligand.^{19,48} As BX represents a unique class of BA ligands with a pK_a that is significantly lower than that of general PBA ligands (Fig. S1†),^{51–53} Au₂₂-BX exhibits better performance under the same pH conditions. Moreover, considering the stability of the biological samples, the BA ligand with a lower pK_a value is more suitable for achieving a binding pH that is more suitable for physiological detection. Thus, in this study, we opted to use BX as the functional ligand to promote stronger interactions with target glycosylated peptides.

The Lewis base in the reaction environment facilitates esterification.⁵⁴ As such, we incorporated a robust Lewis base F⁻ ion into the incubation solution, as it is widely recognized as one of the most effective additives to promote the formation of boronic esters.⁵⁵ As expected, the results confirmed the beneficial effect of F⁻ ion addition with a notably higher binding efficiency (Fig. S13a†). In addition, we optimized other important parameters, such as incubation time and temperature (Fig. S13b and c; Experimental section in ESI†). An incubation

time of 30 min and a temperature of 13 °C were deemed optimal for the incubation procedure.

Boronate affinity methods often encounter undesired non-specific bindings, which can diminish their selectivity.⁵⁶ The presence of negatively charged species on the NC surface can prompt an unexpected adsorption *via* electrostatic interactions. To alleviate this phenomenon, we incorporated NaCl into the washing buffer to enhance the ionic strength of the medium.⁵⁷ In particular, we employed another glycopeptide antibiotic, namely vancomycin, for the control experiments. Vancomycin shares a similar structure with teicoplanin but without a *cis*-diol site, making it a suitable counterpart for the comparison (Fig. S8†). As shown in Fig. 3c, the approach is demonstrated to be effective, as indicated by the higher vancomycin content washed with a higher NaCl concentration. The observed drop at higher concentrations can be attributed to the decreased homogeneity owing to the salting-out effect, resulting in the optimal washing buffer concentration of 0.2 M NaCl. Additionally, the nonspecific bindings induced by charge transfer interactions can be further mitigated by NaF addition (10 mM). A more detailed description and results can be found in the Experimental section in ESI and Fig. S14,† respectively.

2.3. Evaluation of enrichment performance

After optimizing the enrichment protocol, the enrichment performance of our system was further investigated in terms of multiple aspects using standard model peptides. Firstly, considering the extremely low abundance of glycosylated peptides in biological samples, the evolution of the detection sensitivity is crucial for assessing the enrichment efficiency of materials. Teicoplanin at various concentrations was enriched using Au₂₂-BX. Subsequently, the eluted sample was analyzed by MALDI MS to evaluate the sensitivity. Fig. 4 shows teicoplanin peaks with strong signal intensity, and signal peaks, which are detectable at a concentration of as low as 0.01 fmol μL⁻¹ with a reasonable signal-to-noise ratio (S/N = 7.9). Such detection




Fig. 4 Sensitivity evaluation result. MALDI mass spectra of standard peptide (teicoplanin) at different concentrations: (a) 1 fmol μL⁻¹, (b) 0.1 fmol μL⁻¹, and (c) 0.01 fmol μL⁻¹. * denotes a typical peak of teicoplanin.

limit surpasses those reported for other composite materials in previous studies,^{21,22,58,59} including the best results obtained for glycosylated peptide enrichment using magnetic nanoparticles ($1 \text{ fmol } \mu\text{L}^{-1}$).⁵⁸ This demonstrates the high sensitivity obtained, which adequately satisfies the requirements for enriching low-abundance glycosylated peptides. The enhanced sensitivity underscores the superior enrichment capability of our synthesized materials, which are mainly attributed to the ultrasmall size and densely functionalized surface of NCs, facilitating effective interactions with glycosylated peptides.

Enrichment techniques often suffer from undesired non-specific binding owing to the complexity of biological samples, which can limit the detection of target species.^{56,60} As such, we focused on addressing this issue during the optimization of the washing processes, anticipating a high selectivity level. In detail, selectivity was assessed by employing the standard peptide vancomycin as the model interfering species. Teicoplanin was blended with vancomycin at different molar ratios and enriched using the optimized enrichment protocol. With teicoplanin and vancomycin molar ratio of 1 : 100, no teicoplanin signal is detected prior to enrichment owing to the substantial interference (Fig. S15a†). However, distinct desired peaks are noted in the mass spectra after enrichment, even with the extremely high molar ratio of teicoplanin and vancomycin to 1 : 1000 (Fig. S15c†). This selectivity rivals the best performance of previously reported enrichment materials,^{58,61} indicating the sufficiently high selectivity and robust anti-interference capability of our enrichment method.

Considering the significance of developing environmentally and economically sustainable materials across all industries, the reusability of enrichment materials is equally essential. Previous studies have assessed the reusability of their materials for performance evaluation.^{22,23,62} In this work, the reusability of as-prepared Au₂₂-BX was assessed through repetitive Teicoplanin capturing experiments under identical conditions. Au₂₂-BX that underwent the entire enrichment procedure were regenerated with an incubation buffer and purified several times by a 10 kDa desalting column. Subsequently, regenerated Au₂₂-BX were reused to capture the Teicoplanin sample. The results revealed the maintained capture efficiency after five cycles (Fig. 5a and b). In particular, the absorption and PL spectra between the initial and regenerated Au₂₂-BX NCs are maintained (Fig. 5c), confirming the structural stability of Au₂₂-BX throughout the enrichment process. Moreover, the TEM image of regenerated Au₂₂-BX exhibits a uniform distribution, similar to the initial sample, without any apparent aggregation after the enrichment process (Fig. 5d). The test implies the superior reusability of Au₂₂-BX, highlighting their promising potential for practical applications. All these results indicate the outstanding performance of our enrichment method (Table S1†).

2.4. Selective enrichment of glycosylated peptide from human serum

The effective enrichment of the model glycopeptide has prompted us to explore the feasibility of the newly developed




Fig. 5 Evaluation of reusability. (a) Illustration of the recycling of enrichment. (b) Reusability of the materials tested by standard peptide (teicoplanin). The error bar represents the standard error of the mean, as calculated in triplicate. (c) Quality check of regenerated Au₂₂-BX after enrichment experiment by optical absorption spectrometry. Inset: emission spectra ($\lambda_{\text{EX}} = 520 \text{ nm}$) in water. (d) TEM images of the regenerated Au₂₂-BX. The inset shows histograms of the NC core diameter.

NC-based enrichment method in practical applications using human serum to promote the material's utilization in detecting biomarkers associated with disease diagnosis.^{11,60,63} Owing to the relatively low occurrence of glycation *in vivo*, certain glycation sites are difficult to identify, especially when working with limited sample quantities.⁶⁴ Therefore, we incorporated human serum glycosylated *in vitro* to address this limitation. Digested glycosylated human serum sample was used in the analysis without pretreatment. After the enrichment by Au₂₂-BX, the enriched glycosylated peptides were subjected to nanoscale liquid chromatography coupled to tandem MS (LC-MS/MS) analysis. The detected results of triplicate parallel experiments were compared with those of the initial samples (control) to assess the effectiveness of our NC-based enrichment method. The base peak chromatograms obtained from the LC-MS analysis of the peptides are shown in Fig. S16†. Compared with the control, the simplified profile of the enriched sample confirms the effectivity of the NC-based enrichment method for actual biological samples. The detailed results from each sample are summarized in Table 1. First, an average of approximately 82 unique glycosylated peptides were identified from triplicate experiments after enriching each human serum sample, which is a slightly smaller number than that identified from the control sample. However, the ratio of the glycosylated peptides to total peptides significantly increased by more than twofold for the enriched samples, confirming the effectiveness of our enrichment method. Furthermore, the number of identified glycosylated peptide-spectrum matches (PSMs), in which a peptide corresponds to a specific spectrum match, increases in the enriched samples compared to the control. Particularly, a ratio of 14.33% is achieved for glycosylated

Table 1 Selective enrichment of glycosylated peptides from glycosylated human serum sample

Average counts	Control sample	Au ₂₂ -BX enriched
Total peptides	2433	898
Number of glycosylated peptides	106	82
Ratio of glycosylated peptides	(4.31 ± 0.48)%	(8.89 ± 0.94)%
Total PSMs	9824	3502
Number of glycosylated PSMs	322	495
Ratio of glycosylated PSMs	(3.37 ± 0.62)%	(14.33 ± 0.93)%

PSMs after enrichment, which is over four times greater than that of the control (3.37%). The increase in the number of PSMs indicates increased abundance, which indirectly correlates with the target protein quantity in terms of the precursor selection. Previous studies have evaluated the purity of species-specific peptides by examining the changes in the PSM ratios, particularly in the analysis of human-specific peptides.⁶⁵ Therefore, the increase in PSM ratio signifies the increased detection effectivity of the glycosylated peptides and improved reliability of the peptide identification, indicating the effectiveness of the enrichment process for complex human serum samples.

Table 1 shows some impressive enrichment results of Au₂₂-BX. Moreover, critical aspects that need to be addressed in the future are revealed. First, the total PSM and peptide counts in the dataset after enrichment significantly decreased compared to those of the control group. This explains the slight increase in the abundance of glycosylated PSMs and the decrease in that of the glycosylated peptides after enrichment. These results can be ascribed to the presence of unseparated Au₂₂-BX in the enriched PSM and peptide samples that can overestimate of quantities injected for the LC-MS/MS analysis. The enrichment protocol described in Scheme 1 is highly effective for standard peptides, but is less effective for the complex human serum even after several separation trials. Thus, a more effective separation method of Au₂₂-BX should be devised.

Another important aspect of the enrichment result in Table 1 is the significant nonspecific bindings observed in the human serum sample. As discussed above, the Au₂₂-BX enrichment method has excellent selectivity toward glycopeptides in the standard peptide system (Fig. S15†). However, the nonspecific bindings account for more than 91% and 85% of the peptides and PSMs, respectively, of the human serum sample. As those nonspecific bindings may mainly arise from the hydrophilic properties of the tripeptide-type ligand of Au₂₂ NCs, ligand engineering^{30–32,66} of the NCs could be used to reduce the nonspecific bindings.

3. Conclusions

We developed a novel approach that combines BA affinity chemistry with ultrasmall Au NCs for the first time, achieving highly efficient enrichment of early-stage glycosylated peptides with exceptional selectivity and sensitivity. The new enrich-

ment material (Au₂₂-BX) with a pH response and large specific surface area was synthesized by functionalizing Au NCs with BX ligands using a facile post synthetic modification method. Au₂₂-BX exhibited superior enrichment performance, including an ultralow detection limit (0.01 fmol μL⁻¹), high selectivity (teicoplanin/vancomycin = 1/1000, w/w), and excellent reusability. Further experimental results substantiated the ongoing effectiveness of the strategy in enriching the glycosylated proteome, even when dealing with complex biological samples from human serum. Therefore, the novel enrichment strategy based on Au₂₂-BX NCs provided a significant potential for global glycosylated proteome analysis. Further, their remarkable NIR emitting characteristics can be effectively used in visualizing the enrichment process. Notably, the advantages presented by these NCs could pave the way for their application in various proteomics fields, particularly in disease diagnostic and prognostic studies.

Author contributions

H.H., H.L., and D.L. designed the project. H.H., Y.K., and S.A. conducted the NC synthesis and enrichment experiments. S.C. performed the LC-MS/MS analysis. J.M. assisted with the MS analysis. H.L. and D.L. supervised the project. H.H., H.L., and D.L. wrote and revised the manuscript. All authors discussed the results and provided comments on the manuscript at all stages.

Data availability

Most data supporting this article have been included as part of the main text and the ESI.† Additional data that support the findings of this study are available from the corresponding authors upon reasonable request.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korea Government (no. NRF-2022R1A2C3003610) and by Korea Evaluation Institute of Industrial Technology (KEIT) (no. 20018578).

References

- 1 P. Ulrich and A. Cerami, *Recent Prog. Horm. Res.*, 2001, **56**, 1–22.
- 2 A. Twarda-Clapa, A. Olczak, A. M. Białkowska and M. Koziółkiewicz, *Cells*, 2022, **11**, 1312.

- 3 M. Wang, Y. Liang, K. Chen, M. Wang, X. Long, H. Liu, Y. Sun and B. He, *Nanoscale*, 2022, **14**, 2119–2135.
- 4 S. D. Yan, X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher, T. Slattery, L. Zhao, M. Nagashima, J. Morser, A. Migheli, P. Nawroth, D. Stern and A. M. Schmidt, *Nature*, 1996, **382**, 685–691.
- 5 M. A. Smith, S. Taneda, P. L. Richey, S. Miyata, S.-D. Yan, D. Stern, L. M. Sayre, V. M. Monnier and G. Perry, *Proc. Natl. Acad. Sci. U. S. A.*, 1994, **91**, 5710–5714.
- 6 A. Simm, *J. Proteomics*, 2013, **92**, 248–259.
- 7 M. N. Trujillo and J. J. Galligan, *Nat. Chem. Biol.*, 2023, **19**, 922–927.
- 8 T. Niwa, *Mass Spectrom. Rev.*, 2006, **25**, 713–723.
- 9 S. D'Aronco, S. Crotti, M. Agostini, P. Traldi, N. C. Chillelli and A. Lapolla, *Mass Spectrom. Rev.*, 2019, **38**, 112–146.
- 10 R. Schmidt, D. Böhme, D. Singer and A. Frolov, *J. Mass Spectrom.*, 2015, **50**, 613–624.
- 11 S. Cho, V.-A. Duong, J.-H. Mok, M. Joo, J.-M. Park and H. Lee, *Rev. Anal. Chem.*, 2022, **41**, 83–97.
- 12 Q. Zhang, J. M. Ames, R. D. Smith, J. W. Baynes and T. O. Metz, *J. Proteome Res.*, 2009, **8**, 754–769.
- 13 L. Zhang, C.-W. Liu and Q. Zhang, *Anal. Chem.*, 2018, **90**, 1081–1086.
- 14 A. Frolov and R. Hoffmann, *Ann. N. Y. Acad. Sci.*, 2008, **1126**, 253–256.
- 15 Q.-H. Tong, T.-Y. Yan, T. Tao, L. Zhang, L.-Q. Xie and H.-J. Lu, *Anal. Chem.*, 2018, **90**, 3752–3758.
- 16 L. Wu, C. Fang, L. Zhang, W. Yuan, X. Yu and H. Lu, *Anal. Chem.*, 2021, **93**, 4398–4407.
- 17 L. Zhang, Y. Xu, H. Yao, L. Xie, J. Yao, H. Lu and P. Yang, *Chem. – Eur. J.*, 2009, **15**, 10158–10166.
- 18 W. Chen, J. M. Smeekens and R. Wu, *Mol. Cell. Proteomics*, 2014, **13**, 1563–1572.
- 19 H. Li, H. He and Z. Liu, *TrAC, Trends Anal. Chem.*, 2021, **140**, 116271.
- 20 H. Xiao, W. Chen, J. M. Smeekens and R. Wu, *Nat. Commun.*, 2018, **9**, 1692.
- 21 S. Kong, Q. Zhang, L. Yang, Y. Huang, M. Liu, G. Yan, H. Zhao, M. Wu, X. Zhang, P. Yang and W. Cao, *Anal. Chem.*, 2021, **93**, 6682–6691.
- 22 C. Zhang, X. Jin, L. Wang, C. Jin, X. Han, W. Ma, X. Li and G. Teng, *ACS Appl. Mater. Interfaces*, 2021, **13**, 9714–9728.
- 23 L. Yang, Q. Zhang, Y. Huang, L. Lin, H. Schlüter, K. Wang, C. Zhang, P. Yang and H. Yu, *Analyst*, 2020, **145**, 5252–5259.
- 24 R. Jin, *Nanoscale*, 2010, **2**, 343–362.
- 25 H. Qian, M. Zhu, Z. Wu and R. Jin, *Acc. Chem. Res.*, 2012, **45**, 1470–1479.
- 26 R. W. Murray, *Chem. Rev.*, 2008, **108**, 2688–2720.
- 27 P. Maity, S. Xie, M. Yamauchi and T. Tsukuda, *Nanoscale*, 2012, **4**, 4027–4037.
- 28 I. Chakraborty and T. Pradeep, *Chem. Rev.*, 2017, **117**, 8208–8271.
- 29 K. Kwak and D. Lee, *Acc. Chem. Res.*, 2019, **52**, 12–22.
- 30 S. Li, W. Tian and Y. Liu, *Nanoscale*, 2021, **13**, 16847–16859.
- 31 S. M. Han, M. Park, J. Kim and D. Lee, *Angew. Chem., Int. Ed.*, 2024, e202404387.
- 32 K. Pyo, V. D. Thanthirige, S. Y. Yoon, G. Ramakrishna and D. Lee, *Nanoscale*, 2016, **8**, 20008–20016.
- 33 X. Kang and M. Zhu, *Chem. Soc. Rev.*, 2019, **48**, 2422–2457.
- 34 K. Pyo, H. Xu, S. M. Han, S. Saxena, S. Y. Yoon, G. Wiederrecht, G. Ramakrishna and D. Lee, *Small*, 2021, **17**, 2004836.
- 35 Z. Liu, J. Chen, B. Li, D.-E. Jiang, L. Wang, Q. Yao and J. Xie, *J. Am. Chem. Soc.*, 2024, **146**, 11773–11781.
- 36 H. Liu, G. Hong, Z. Luo, J. Chen, J. Chang, M. Gong, H. He, J. Yang, X. Yuan, L. Li, X. Mu, J. Wang, W. Mi, J. Luo, J. Xie and X.-D. Zhang, *Adv. Mater.*, 2019, **31**, 1901015.
- 37 S. Li, J. Wei, Q. Yao, X. Song, J. Xie and H. Yang, *Chem. Soc. Rev.*, 2023, **52**, 1672–1696.
- 38 J. Liu, M. Yu, C. Zhou, S. Yang, X. Ning and J. Zheng, *J. Am. Chem. Soc.*, 2013, **135**, 4978–4981.
- 39 M. Yu and J. Zheng, *ACS Nano*, 2015, **9**, 6655–6674.
- 40 C. V. Conroy, J. Jiang, C. Zhang, T. Ahuja, Z. Tang, C. A. Prickett, J. J. Yang and G. Wang, *Nanoscale*, 2014, **6**, 7416–7423.
- 41 K. Pyo, N. H. Ly, S. Y. Yoon, Y. Shen, S. Y. Choi, S. Y. Lee, S. W. Joo and D. Lee, *Adv. Healthcare Mater.*, 2017, **6**, 1700203.
- 42 K. Pyo, N. H. Ly, S. M. Han, M. B. Hatshan, A. Abuhagr, G. Wiederrecht, S.-W. Joo, G. Ramakrishna and D. Lee, *J. Phys. Chem. Lett.*, 2018, **9**, 5303–5310.
- 43 K. Pyo, V. D. Thanthirige, K. Kwak, P. Pandurangan, G. Ramakrishna and D. Lee, *J. Am. Chem. Soc.*, 2015, **137**, 8244–8250.
- 44 K. Pyo, S. M. Han, H. Xu, S. Saha, G. Ramakrishna and D. Lee, *Sol. RRL*, 2021, **5**, 2000710.
- 45 J. Arnaud, A. Audfray and A. Imberty, *Chem. Soc. Rev.*, 2013, **42**, 4798–4813.
- 46 S. Jin, Y. Cheng, S. Reid, M. Li and B. Wang, *Med. Res. Rev.*, 2010, **30**, 171–257.
- 47 D. Bruen, C. Delaney, D. Diamond and L. Florea, *ACS Appl. Mater. Interfaces*, 2018, **10**, 38431–38437.
- 48 M. B. Espina-Benitez, J. Randon, C. Demesmay and V. Dugas, *Sep. Purif. Rev.*, 2017, **47**, 214–228.
- 49 K. Ariei, T. Kai and Y. Kokuba, *Eur. J. Pharm. Sci.*, 1999, **7**, 107–112.
- 50 M. Dowlut and D. G. Hall, *J. Am. Chem. Soc.*, 2006, **128**, 4226–4227.
- 51 X. Qin, Z. Zhang, H. Shao, R. Zhang, L. Chen and X. Yang, *Analyst*, 2020, **145**, 7511–7527.
- 52 W. L. A. Brooks, C. C. Deng and B. S. Sumerlin, *ACS Omega*, 2018, **3**, 17863–17870.
- 53 T. Figueiredo, Y. Ogawa, J. Jing, V. Cosenza, I. Jeacomine, J. D. M. Olsson, T. Gerfaud, J.-G. Boiteau, C. Harris and R. Auzély-Velty, *Polym. Chem.*, 2020, **11**, 3800–3811.
- 54 L. Ren, Z. Liu, M. Dong, M. Ye and H. Zou, *J. Chromatogr. A*, 2009, **1216**, 4768–4774.
- 55 P. R. Westmark, L. S. Valencia and B. D. Smith, *J. Chromatogr. A*, 1994, **664**, 123–128.

- 56 D. Li, Y. Chen and Z. Liu, *Chem. Soc. Rev.*, 2015, **44**, 8097–8123.
- 57 R. J. Carvalho, J. Woo, M. R. Aires-Barros, S. M. Cramer and A. M. Azevedo, *Biotechnol. J.*, 2014, **9**, 1250–1258.
- 58 L. Wu, W. Fei, Z. Liu, L. Zhang, C. Fang and H. Lu, *Anal. Chem.*, 2022, **94**, 5213–5220.
- 59 P. Su, M. Li, X. Li, X. Yuan, Z. Gong, L. Wu, J. Song and Y. Yang, *J. Chromatogr. A*, 2022, **1667**, 462869.
- 60 Y. Zhang, J. Jiao, P. Yang and H. Lu, *Clin. Proteomics*, 2014, **11**, 18.
- 61 Z. Gao, R. Tang, S. Ma, S. Jia, S. Zhang, B. Gong and J. Ou, *Anal. Methods*, 2021, **13**, 4515–4527.
- 62 S. Saleem, M. S. Sajid, D. Hussain, F. Jabeen, M. Najam-ul-Haq and A. Saeed, *Anal. Bioanal. Chem.*, 2020, **412**, 1509–1520.
- 63 J. Jeon, J. Yang, J.-M. Park, N.-Y. Han, Y.-B. Lee and H. Lee, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2018, **1092**, 88–94.
- 64 Q. Zhang, M. E. Monroe, A. A. Schepmoes, T. R. W. Clauss, M. A. Gritsenko, D. Meng, V. A. Petyuk, R. D. Smith and T. O. Metz, *J. Proteome Res.*, 2011, **10**, 3076–3088.
- 65 Z. Shi, B. Mao, X. Chen, P. Hao and S. Guo, *Cancer Res. Commun.*, 2023, **3**, 202–214.
- 66 B. Zhang, J. Chen, Y. Cao, O. J. H. Chai and J. Xie, *Small*, 2021, **17**, 2004381.